Cabaletta Bio (CABA) Shares Outstanding (Weighted Average) (2018 - 2025)
Cabaletta Bio (CABA) recorded quarterly Shares Outstanding (Weighted Average) of $53.1 million in Q4 2025, up 784.84% quarter-over-quarter from $6.0 million in Q3 2025.
Cabaletta Bio (CABA) Shares Outstanding (Weighted Average) (2018 - 2025) Analysis & Trends
Cabaletta Bio's Shares Outstanding (Weighted Average) history runs 8 years deep, the most recent figure standing at $53.1 million for Q4 2025.
- In Q4 2025, Shares Outstanding (Weighted Average) changed N/A year-over-year to $53.1 million; the TTM figure through Dec 2025 stood at $53.1 million (changed N/A YoY), while the FY2025 annual figure was $53.1 million, changed N/A from the prior year.
- Shares Outstanding (Weighted Average) was $53.1 million for Q4 2025 at Cabaletta Bio, up from $6.0 million in the prior quarter.
- In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $53.1 million in Q4 2025 to a low of $624574.0 in Q3 2024.
- Historically, Shares Outstanding (Weighted Average) has averaged $15.4 million across 5 years, with a median of $4.6 million in 2021.
- The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Weighted Average) tumbled 83.56% in 2023, then jumped 1071.75% in 2024.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $21.4 million in 2021, then slumped by 82.68% to $3.7 million in 2022, then tumbled by 68.42% to $1.2 million in 2023, then tumbled by 46.53% to $624574.0 in 2024, then surged by 8400.22% to $53.1 million in 2025.
- The last three Shares Outstanding (Weighted Average) figures came in at $53.1 million (Q4 2025), $6.0 million (Q3 2025), and $10.8 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 185,491.37 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 400.00 Bn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 100.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 417.01 Bn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 68.88 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 254.10 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 928.40 Mn |
| 10 | Cabaletta Bio | 151.84 Mn | 18.24 Mn | - | 53.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 53.09 Mn |
| Sep 30, 2025 | 6.00 Mn |
| Jun 30, 2025 | 10.80 Mn |
| Sep 30, 2024 | 624,574.00 |
| Jun 30, 2024 | 48.40 Mn |
| Mar 31, 2024 | 47.86 Mn |
| Dec 31, 2023 | 1.17 Mn |
| Sep 30, 2023 | 2.35 Mn |
| Jun 30, 2023 | 4.13 Mn |
| Mar 31, 2023 | 4.13 Mn |
| Sep 30, 2022 | 3.70 Mn |
| Jun 30, 2022 | 25.13 Mn |
| Mar 31, 2022 | 4.11 Mn |
| Dec 31, 2021 | 21.36 Mn |
| Sep 30, 2021 | 4.40 Mn |
| Jun 30, 2021 | 20.42 Mn |
| Mar 31, 2021 | 4.57 Mn |
| Dec 31, 2020 | 5.73 Mn |
| Sep 30, 2020 | 17.83 Mn |
| Jun 30, 2020 | 6.41 Mn |